Your session is about to expire
← Back to Search
Monoclonal Antibodies
secukinumab high dose for Chronic Plaque-type Psoriasis
Phase 3
Waitlist Available
Research Sponsored by Novartis Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baleine, weeks 4, 12, 13, 14, 15, 16, 24, 52, 104, 156, 208
Awards & highlights
Study Summary
This trial was testing a new medication for plaque psoriasis in children aged 6 to 18. 84 subjects were enrolled and most had moderate severity.
Eligible Conditions
- Moderate to Severe Chronic Plaque-type Psoriasis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baleine, weeks 4, 12, 13, 14, 15, 16, 24, 52, 104, 156, 208
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baleine, weeks 4, 12, 13, 14, 15, 16, 24, 52, 104, 156, 208
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Number and Percentage of Participants With IGA Mod 2011 0 or 1 Response
Number and Percentage of Participants With PASI 75 Response
Secondary outcome measures
Number and Percentage of Participants With PASI 90 Response
Secukinumab Concentration in Serum
Summary Table of Adverse Events
Trial Design
2Treatment groups
Experimental Treatment
Group I: secukinumab low doseExperimental Treatment1 Intervention
secukinumab low dose
Group II: secukinumab high doseExperimental Treatment1 Intervention
secukinumab high dose
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Secukinumab
FDA approved
Secukinumab
FDA approved
Find a Location
Who is running the clinical trial?
Novartis PharmaceuticalsLead Sponsor
2,866 Previous Clinical Trials
4,199,242 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- The researcher thinks you might need medication that affects your whole body.You are currently taking medications that are not allowed in this study.Your psoriasis must be the chronic plaque type and active at the time of enrollment. Other forms of psoriasis are not allowed.You have psoriasis caused by a medication.
Research Study Groups:
This trial has the following groups:- Group 1: secukinumab high dose
- Group 2: secukinumab low dose
Awards:
This trial has 3 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger